S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:CNAT

Conatus Pharmaceuticals (CNAT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.47
$0.56
50-Day Range
$0.56
$1.34
52-Week Range
$0.23
$1.07
Volume
553,713 shs
Average Volume
1.28 million shs
Market Capitalization
$18.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CNAT stock logo

About Conatus Pharmaceuticals (NASDAQ:CNAT) Stock

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.


CNAT Stock News Headlines

Get Your Cash Out of U.S. Banks Immediately
Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
CNAT Jan 2021 2.500 call
CNAT Oct 2020 2.500 call
News for Conatus Pharmaceuticals Inc
Get Your Cash Out of U.S. Banks Immediately
Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
Histogen completes tie-up with Conatus Pharma
Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc.
Histogen to Present at BIO CEO & Investor Conference
Conatus to merge with Histogen
116 Healthcare Stocks Moving In Wednesday's Session
See More Headlines
Receive CNAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNAT Company Calendar

Last Earnings
5/01/2020
Today
9/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNAT
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-11,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.72 million
Book Value
$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$18.14 million
Optionable
Optionable
Beta
1.84
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Steven J. Mento (Age 67)
    Co-Founder, Pres, CEO & Director
  • Dr. Keith W. Marshall MBA (Age 51)
    Ph.D., Exec. VP, COO & CFO
  • Dr. David T. Hagerty (Age 64)
    Exec. VP of Clinical Devel.
  • Dr. Alfred P. Spada (Age 61)
    Co-Founder, Exec. VP of R&D and Chief Scientific Officer
  • Mr. Alan R. Engbring
    Exec. Director of Investor Relations & Corp. Communications













CNAT Stock - Frequently Asked Questions

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%.

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN).

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $0.55.

How much money does Conatus Pharmaceuticals make?

Conatus Pharmaceuticals (NASDAQ:CNAT) has a market capitalization of $18.14 million and generates $21.72 million in revenue each year.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The official website for the company is www.conatuspharma.com. The biotechnology company can be reached via phone at 858-376-2600 or via email at aengbring@conatuspharma.com.

This page (NASDAQ:CNAT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -